Abemaciclib (7) – Verzenios®

Breast cancer, HR+, HER2-, early-stage with a high risk of recurrence, adjuvant therapy, combination with endocrine therapy

Characteristics

Start date 01.03.2026
Resolution 20.08.2026 – active procedure
INN Abemaciclib
Brand name Verzenios®
Pharm. company Lilly Deutschland GmbH
G-BA Procedure ID D-1303
Therapeutic area Oncological diseases
Reason for procedure Reassessment: G-BA limitation

Associated procedures

Abemaciclib (7) Verzenios® Lilly Deutschland GmbH Oncological diseases Breast cancer, HR+, HER2-, early-stage with a high risk of recurrence, adjuvant therapy, combination with endocrine therapy n.d. active procedure
Abemaciclib (6) Verzenios® Lilly Deutschland GmbH Oncological diseases Breast carcinoma (BC), HR+, HER2-, combination with aromatase inhibitor 7,400–34,790 100% Hint for minor additional benefit
Abemaciclib (5) Verzenios® Lilly Deutschland GmbH Oncological diseases Breast cancer (BC), HR+, HER2-, early with high risk of recurrence, adjuvant, combination with endocrine therapy 6,905–9,435 40% Hint for minor additional benefit
Abemaciclib (4) Verzenios® Lilly Deutschland GmbH Oncological diseases Breast cancer (BC), HR+, HER2-, combination with fulvestrant 12,870–59,690 42% Indication of minor additional benefit
Abemaciclib (3) Verzenios® Lilly Deutschland GmbH Oncological diseases Mammary carcinoma, HR+, HER2-, combination with fulvestrant 906–4,118
13,776–63,808 		39% Hint for minor additional benefit repealed subpopulations
Abemaciclib (2) Verzenios® Lilly Deutschland GmbH Oncological diseases Breast cancer (BC), HR+, HER2-, combination with fulvestrant 14,560–70,550 100% additional benefit not proven
Abemaciclib (1) Verzenios® Lilly Deutschland GmbH Oncological diseases Breast cancer (BC), HR+, HER2-, combination with aromatase inhibitor 14,560–70,550 100% additional benefit not proven


<< List of all resolutions